Last updated: September 8, 2026
Insulin isophane human, commonly called NPH insulin, is a mature intermediate-acting human insulin with low patent risk, limited innovation protection, and declining strategic importance in developed markets. The principal commercial products are Humulin N from Eli Lilly, Novolin N from Novo Nordisk, and ReliOn-branded Novolin N sold through Walmart. Revenue is concentrated in established products and private-label channels rather than protected innovation.
NPH remains commercially relevant because it is inexpensive, widely available, included in many public-health formularies, and used where newer basal insulins are unaffordable. Its market position is pressured by insulin glargine, insulin degludec, insulin detemir, biosimilar and follow-on basal insulins, and lower-cost human insulin programs.
What is insulin isophane human and how is it used?
Insulin isophane human is a recombinant human insulin formulated with protamine and zinc to delay absorption after subcutaneous injection. It is also known as neutral protamine Hagedorn, or NPH insulin.
| Attribute |
Product profile |
| Active ingredient |
Human insulin, isophane suspension |
| Pharmacologic class |
Intermediate-acting insulin |
| Typical onset |
Approximately 1 to 2 hours |
| Typical duration |
Approximately 12 to 18 hours, with substantial patient variability |
| Principal indications |
Type 1 and type 2 diabetes |
| Administration |
Subcutaneous injection |
| Principal U.S. products |
Humulin N, Novolin N, ReliOn Novolin N |
| Regulatory category |
Historically approved as insulin NDAs; insulin products transitioned to the biologics framework under the Public Health Service Act |
| Main commercial weakness |
Variable action and higher nocturnal hypoglycemia risk than newer basal analogues |
| Main commercial strength |
Low acquisition cost and broad availability |
NPH is often administered once or twice daily. It is also used in premixed products such as 70/30 human insulin, which combines NPH with regular human insulin.
Which companies market insulin isophane human?
Eli Lilly and Novo Nordisk control the principal branded and private-label U.S. supply.
Eli Lilly: Humulin N
Humulin N is marketed in vials and pen presentations. Lilly’s product has long-standing physician familiarity and distribution through retail pharmacies, wholesalers, Medicaid channels, and discount programs.
Lilly’s commercial strategy has shifted from premium pricing toward access and affordability. In 2023, the company announced a 70% reduction in the list price of insulin products, including Humulin products, and introduced a $35 monthly insulin cap for eligible patients through its affordability program.[1]
Novo Nordisk: Novolin N
Novolin N is available in vials and FlexPen presentations. Novo Nordisk also supplies insulin isophane human sold under Walmart’s ReliOn brand.
The ReliOn channel is strategically important because it gives NPH insulin direct exposure to cash-paying patients and consumers seeking low-cost diabetes treatment. Walmart has marketed ReliOn Novolin insulin at prices substantially below many branded retail alternatives.[2]
Other suppliers and regional manufacturers
Human insulin products may also be supplied by regional manufacturers, contract manufacturers, and public-sector procurement systems outside the United States. Availability varies by country, and many markets use recombinant human insulin supplied through government tenders rather than conventional branded retail channels.
What is the FDA regulatory status of insulin isophane human?
FDA-approved NPH products are established insulin products, not new molecular entities. The FDA regulates insulin under the biologics framework, although many legacy insulin products were originally approved as new drug applications before the statutory transition.
The main U.S. products have been approved for decades:
| Product |
Sponsor |
Dosage forms |
Regulatory position |
| Humulin N |
Eli Lilly |
Vial, pen |
Established human insulin product |
| Novolin N |
Novo Nordisk |
Vial, pen |
Established human insulin product |
| ReliOn Novolin N |
Novo Nordisk supply, Walmart brand |
Vial, pen |
Private-label distribution |
| NPH-containing premixes |
Primarily Lilly and Novo Nordisk |
Vial, pen |
Established combination insulin products |
FDA approval does not create meaningful modern exclusivity for these products. Any current market protection comes mainly from manufacturing scale, supply contracts, distribution, brand familiarity, and regulatory compliance.
What patents protect insulin isophane human?
The original patent estate for recombinant human insulin, protamine formulations, and NPH manufacturing is largely expired. NPH insulin has been marketed for several decades, placing the core composition and basic formulation rights well beyond the ordinary 20-year patent term.
Patent protection profile
| Patent category |
Current commercial relevance |
| Recombinant human insulin sequence |
Core rights expired |
| Protamine-based NPH suspension |
Core rights expired |
| Basic zinc and protamine formulation |
Core rights expired |
| Conventional vial presentation |
No meaningful patent barrier |
| Pen-device presentation |
Potential device patents may exist, but they do not protect NPH as an active ingredient |
| Manufacturing process |
Process know-how and quality systems remain relevant; broad blocking patents are unlikely to be central |
| Premixed NPH/regular insulin |
Core product rights are mature; device and formulation improvements may have separate rights |
| Drug-delivery systems |
Current patents may cover specific pens, needles, cartridges, or connected devices |
The principal commercial distinction is between product patents and operational know-how. A competitor does not need to reproduce a branded pen device to compete with NPH insulin in a vial. It must meet FDA requirements for identity, strength, purity, potency, sterility, stability, device performance, and batch consistency.
When does insulin isophane human lose exclusivity?
NPH insulin lost meaningful product exclusivity decades ago. Humulin N and Novolin N are mature products with no remaining effective new-molecule exclusivity.
| Exclusivity category |
Status |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
Not commercially relevant to the core product |
| New product exclusivity |
Expired or unavailable for legacy formulations |
| Core composition patents |
Expired |
| Basic NPH formulation patents |
Expired |
| Device patents |
May apply to individual pens or cartridges, not the underlying insulin |
| Regulatory market access |
Open to qualifying follow-on applicants |
The commercial market therefore operates under mature-product economics. Price, supply reliability, procurement access, and manufacturing capability are more important than patent expiration dates.
What is the Orange Book status of Humulin N and Novolin N?
The Orange Book is not the principal source of market protection for these products. Legacy insulin products were approved under the drug framework, but FDA’s insulin transition moved insulin products into the biologics framework. Current competitive analysis should therefore consider the Purple Book and the FDA’s insulin biosimilar and interchangeable-product pathway, not only conventional Orange Book listing data.[3]
A competitor seeking approval for a comparable insulin product may use a biologics pathway, including a biosimilar pathway where applicable. The regulatory route depends on the reference product, formulation, presentation, and manufacturing evidence.
Are there Paragraph IV challenges to insulin isophane human?
Paragraph IV litigation is not a significant current risk for the core NPH product. The relevant composition and formulation rights have expired, and the principal commercial products are not protected by a modern Orange Book patent structure comparable to newer small-molecule medicines.
Potential disputes could still arise over:
- Device patents for insulin pens;
- Cartridge and delivery-system patents;
- Manufacturing processes;
- Trade secrets involving cell lines, purification, crystallization, or suspension control;
- Regulatory exclusivity for a newly developed formulation;
- Trademark and private-label distribution rights.
These issues would affect a specific presentation or manufacturer, not the fundamental availability of NPH insulin.
Is insulin isophane human exposed to biosimilar competition?
Yes, but the competitive effect is different from the biosimilar risk facing a high-value biologic with active patents.
Insulin isophane human is vulnerable to follow-on competition because its clinical profile is well understood, its core patents are expired, and its manufacturing technology is established. The principal barriers are regulatory comparability, commercial-scale production, quality control, and distribution.
The more important competitive threat comes from basal insulin analogues and lower-cost follow-on versions of insulin glargine, not from a wave of newly launched NPH biosimilars. Insulin glargine products, including authorized generics and biosimilar or interchangeable products, can displace NPH where payers value flatter pharmacokinetics and lower hypoglycemia risk.
Why NPH has not been displaced completely
NPH retains demand because:
- It is cheaper than many analogues.
- It is available in low-cost vial formats.
- It is familiar to clinicians.
- It is used in resource-constrained health systems.
- It remains included in many formularies and procurement programs.
- It can be used in pregnancy under established clinical protocols, subject to local labeling and clinical judgment.
What formulations are protected by patents?
The fundamental NPH suspension is not meaningfully protected by active composition patents. Potentially protected elements are more likely to involve delivery systems and specific product configurations.
Formulation and device risk areas
| Area |
Risk assessment |
| Insulin plus protamine suspension |
Low core patent risk |
| Zinc concentration and suspension control |
Low to moderate, depending on specific claim scope |
| Premixed 70/30 formulations |
Low for legacy products; possible device or process rights |
| Disposable pens |
Moderate device-specific risk |
| Reusable pens and cartridges |
Moderate device-specific risk |
| Needle-shielding and injection mechanisms |
Separate device patent analysis required |
| Connected insulin delivery |
Higher potential patent density, but not specific to NPH’s core molecule |
| Stability and packaging |
Possible narrow patents; manufacturing compliance remains more important |
A company entering the vial market faces a lower intellectual-property burden than a company launching a substantially identical pen presentation.
How strong is the patent estate for insulin isophane human?
The core patent estate is weak from an exclusion standpoint. The operational moat is stronger than the legal moat.
| Factor |
Assessment |
| Core composition patents |
Very weak or expired |
| Basic formulation patents |
Weak or expired |
| Regulatory exclusivity |
None of commercial significance |
| Manufacturing complexity |
Moderate to high |
| Quality and consistency requirements |
High |
| Device-specific rights |
Variable |
| Brand loyalty |
Moderate |
| Distribution access |
High importance |
| Switching friction |
Moderate, particularly for patients using pens or established titration protocols |
| Litigation leverage |
Low for the core product |
Insulin manufacturing requires biological production, purification, formulation, sterile filling, analytical testing, and validated cold-chain operations. These requirements can deter entry even when patents do not.
What is the market size and financial trajectory for insulin isophane human?
Public companies generally do not report revenue for NPH insulin as a separate line item. Lilly reports broader diabetes and insulin revenue, while Novo Nordisk reports diabetes and obesity portfolios and selected product categories rather than a complete standalone figure for Novolin N.
As a result, the NPH market cannot be valued reliably from public company filings alone. The financial trajectory is best assessed through observable commercial drivers:
| Driver |
Effect on NPH financial performance |
| Lower list prices |
Reduces unit revenue and gross margin |
| Medicaid and government purchasing |
Increases volume but compresses price |
| Walmart ReliOn distribution |
Expands cash-pay access and increases price competition |
| Basal insulin analogue adoption |
Reduces NPH volume in developed markets |
| Diabetes prevalence |
Supports underlying demand |
| Human insulin use in emerging markets |
Supports volume growth |
| Manufacturing disruptions |
Can create temporary pricing and availability benefits |
| Biosimilar and follow-on insulin competition |
Increases long-term price pressure |
| Pen adoption |
Raises unit economics but increases device competition |
| Public-sector tenders |
Favor scale and low cost over brand premiums |
Lilly’s 2023 pricing actions are a direct signal that insulin manufacturers face political, payer, and competitive pressure to reduce patient out-of-pocket costs.[1] The move supports volume retention and access but limits the ability to preserve premium pricing for legacy human insulin.
Financial outlook by market
United States
The U.S. NPH market is mature and price-sensitive. Growth is likely to be flat to declining in value terms, with any unit growth offset by price reductions and migration to insulin analogues. ReliOn and other cash-pay channels intensify competition.
Europe
NPH use remains established but is generally under pressure from basal analogues and national reimbursement policies. Tendering and health-technology assessment favor products with demonstrated economic value and predictable supply.
Emerging markets
Emerging markets offer the strongest volume opportunity. Human insulin often remains more affordable than analogues, and public procurement programs can favor NPH and regular human insulin. Revenue per unit is lower, but population growth, rising diabetes prevalence, and expanded diagnosis can support demand.
Which companies are challenging the NPH market?
Competition comes from both direct human-insulin products and alternative basal therapies.
| Competitor category |
Representative companies or products |
Competitive effect |
| Branded NPH |
Eli Lilly Humulin N; Novo Nordisk Novolin N |
Direct competition |
| Private-label NPH |
ReliOn Novolin N |
Low-price channel pressure |
| Basal insulin analogues |
Lantus, Toujeo, Basaglar, Semglee, Tresiba |
Clinical and formulary substitution |
| Human premixes |
Humulin 70/30, Novolin 70/30 |
Retain low-cost insulin users |
| Biosimilar or follow-on basal insulin |
Insulin glargine follow-on products |
Reduces the price gap versus NPH |
| Non-insulin diabetes drugs |
GLP-1 receptor agonists, SGLT2 inhibitors, other agents |
Reduce or delay insulin initiation in some type 2 patients |
| Regional insulin manufacturers |
Country-specific human insulin suppliers |
Increase procurement competition |
The most direct strategic threat is not a patent challenger. It is a lower-priced basal analogue or a payer policy that shifts patients away from NPH while maintaining acceptable cost.
What generic launch risks exist for insulin isophane human?
A new entrant could launch through a qualifying biologics or insulin pathway without waiting for core NPH patents to expire. The main launch risks are commercial and technical.
Entry barriers
- Establishing a reliable recombinant insulin supply chain;
- Demonstrating product quality and comparability;
- Meeting sterile manufacturing requirements;
- Securing device and cartridge rights;
- Obtaining reimbursement and formulary placement;
- Matching incumbent supply reliability;
- Building physician and pharmacy distribution;
- Managing cold-chain logistics;
- Avoiding immunogenicity and potency failures;
- Competing against low-price incumbents.
A generic-style launch into the vial segment is more feasible than a differentiated pen launch. The low price of incumbent NPH products can also make return on investment unattractive for a new entrant.
What patent litigation affects insulin isophane human?
No major current patent litigation is central to the global NPH market. The product’s litigation profile is low compared with newer biologics, insulin delivery systems, and GLP-1 medicines.
Disputes more likely to affect NPH economics would involve:
- Contract manufacturing;
- Supply interruptions;
- Distribution agreements;
- State or federal insulin pricing rules;
- Device patents;
- Trademark rights involving private-label products;
- Product liability or manufacturing-quality claims.
Patent litigation is more relevant to competing basal analogues, insulin pens, automated delivery systems, and connected diabetes devices than to the NPH molecule itself.
Are there licensing deals involving insulin isophane human?
The principal commercial arrangements are manufacturing, distribution, private-label, and procurement agreements rather than licenses to active NPH patents.
The Walmart ReliOn relationship with Novo Nordisk is the clearest commercial example of private-label distribution. Lilly and Novo Nordisk also participate in pharmacy, wholesaler, insurer, and government affordability programs. Public disclosures generally do not isolate the economics of NPH-specific agreements.
No major current license appears to create a durable patent-based monopoly over NPH insulin.
How does NPH insulin compare with insulin glargine?
| Metric |
Insulin isophane human |
Insulin glargine |
| Duration |
Intermediate |
Long-acting |
| Dosing |
Often once or twice daily |
Usually once daily |
| Action variability |
Higher |
Lower |
| Nocturnal hypoglycemia risk |
Generally higher |
Generally lower |
| Core patent position |
Expired |
Original patents expired, but newer device and product competition remains |
| Price |
Usually lower |
Historically higher, now pressured by follow-on products |
| Use in low-income settings |
Strong |
Increasing where affordable |
| Commercial growth |
Mature or declining in developed markets |
More resilient, though price competition is rising |
| Manufacturing barrier |
High |
High |
| Main advantage |
Affordability |
Pharmacokinetic predictability and convenience |
NPH remains defensible as a low-cost product. It is less defensible as a premium product.
What is the generic entry and geographic outlook?
The strongest entry opportunity is in markets where:
- NPH is purchased through government tenders;
- Analogues remain unaffordable;
- Local manufacturing is supported;
- Private-label distribution is underdeveloped;
- Diabetes diagnosis and insulin access are expanding.
The weakest opportunity is in high-income markets where NPH is already sold at low prices and basal analogues have broad reimbursement.
A new manufacturer is more likely to succeed through institutional supply, regional tenders, or a private-label partnership than through a conventional branded launch in the U.S.
Key Takeaways
- Insulin isophane human is a mature recombinant human insulin product with expired core composition and formulation protection.
- Humulin N, Novolin N, and ReliOn Novolin N are the principal U.S. commercial products.
- No meaningful modern new-molecule exclusivity or Paragraph IV patent risk remains.
- The strongest barriers are manufacturing quality, sterile production, supply reliability, reimbursement, and distribution.
- NPH revenue is not separately disclosed by Lilly or Novo Nordisk, so product-level market size and revenue cannot be inferred reliably from filings.
- U.S. value growth is likely to remain weak because of price reductions, private-label competition, and substitution by basal analogues.
- Emerging markets offer better volume prospects because NPH remains an affordable insulin option.
- The main competitive threat is insulin glargine and other basal therapies, not a new patent challenger to NPH.
- Pen and delivery-system patents can affect a specific presentation even when the underlying NPH product is unprotected.
- A new entrant has the best prospects through tenders, private-label distribution, or regional manufacturing.
FAQs
Is insulin isophane human the same as NPH insulin?
Yes. Insulin isophane human is the regulatory and product name commonly associated with neutral protamine Hagedorn, or NPH, insulin.
Can a company launch a competing NPH insulin without licensing Lilly or Novo Nordisk?
A company may be able to launch a competing product without licensing expired core NPH patents, but it must obtain regulatory approval and avoid active device, manufacturing, trademark, and distribution rights.
Does insulin isophane human have biosimilar exclusivity?
No material biosimilar exclusivity protects the mature NPH product. Competition depends on the applicable FDA pathway and the specific reference product.
Which NPH insulin is cheapest in the United States?
ReliOn Novolin N has historically been positioned as a low-cost option, while Lilly and Novo Nordisk have reduced prices and expanded affordability programs. Actual patient cost depends on cash pricing, insurance, pharmacy, eligibility, and product presentation.
Is NPH insulin likely to disappear from the market?
NPH is unlikely to disappear in the near term. Its low cost, established manufacturing base, and use in public-sector and lower-income markets support continued demand, even as its share declines in markets that favor long-acting analogues.
References
-
Eli Lilly and Company. (2023, March 1). Lilly insulins to be available for $35 a month for people with commercial insurance and no insurance. https://www.lilly.com/news/stories/insulin-affordability
-
Walmart. (n.d.). ReliOn insulin products. https://www.walmart.com/cp/relion/443984
-
U.S. Food and Drug Administration. (2020). Insulin and insulin products: Transitioning to the biologics regulatory pathway. https://www.fda.gov/drugs/drug-safety-and-availability/insulin-and-insulin-products
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
